Facebook
Twitter
LinkedIn
ForwardThe Journal of Urology® Volumes 195/196 Home Study Course (2016)
Most Comprehensive and Affordable Self-study CME Product!
Make the most of your Journal of Urology® Subscription
Developed by a team of educators, academicians, and clinicians, this valuable home study activity will enhance your knowledge of urology and improve performance as well as patient care at your convenience. For just $2.50 per credit, the Home Study program is designed to provide urologists and residents affordable access to the most recent developments and techniques in urology while reading The Journal®.
Each month includes 5 clinically-relevant, selected articles with a corresponding online test for each of the 12 issues of The Journal®.
The American Urological Association designates this enduring material for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Home Study Course is available only to subscribers of The Journal of Urology® and includes volumes 195 and 196.
Target Audience
This course is designed for:
- Practicing Urologists
- American Board of Urology (ABU) candidates
- Residents
Learning Objectives
After completing each lesson, the participants should be able to:
- Assess their knowledge of urology
- Demonstrate an increased knowledge base of urology
- Apply the increased knowledge to improve quality of patient care
Disclosures
(Individuals in control of the content. All individuals with their respective disclosures listed in this document are planners. Individual authors’ disclosures are located with their articles in each issue of The Journal of Urology®.)
Planner Disclosures
Victor Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial
Tracey Krupski, MD: Argos: Scientific Study or Trial; NCI-RAZOR: Scientific Study or Trial
The Journal of Urology® Editorial Board
Karl-Erik Andersson, M.D., Ph.D.: Astellas, Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Ferring: Consultant or Advisor, Meeting Participant or Lecturer
Daniel Ari Barocas, M.D.: Janssen: Consultant or Advisor; Tolmar: Consultant or Advisor
Laurence Seth Baskin MD: Nothing to disclose
Peter Colin Black, M.D.: GenomeDx Biosciences Inc: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Amgen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sitka: Consultant or Advisor; Ferring: Consultant or Advisor, Meeting Participant or Lecturer; AbbVie: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; RedLeaf Medical: Meeting Participant or Lecturer; Novartis: Meeting Participant or Lecturer; Biocancell: Consultant or Advisor; Cubist: Consultant or Advisor; Roche/Genentech: Scientific Study or Trial; World Journal of Urology: Health Publishing; Urologic Oncology: Health Publishing; Bladder Cancer: Health Publishing; PLOS ONE: Health Publishing; BMC Urology: Health Publishing
Robert Edward Brannigan MD: The American Society for Reproductive Medicine (ASRM): Leadership Position, Health Publishing; The American Society for Reproductive Medicine: Leadership Position; AbbVie, Inc.: Other; The National Institutes of Health: Other
Toby C. Chai, MD: Ion Channel, Inc.: Consultant or Advisor; Allergan: Consultant or Advisor
Peter Earl Clark, M.D.: Galil Medical: Consultant or Advisor; Genentech: Consultant or Advisor
Craig Vance Comiter, M.D.: coloplast: Consultant or Advisor; axiom: Consultant or Advisor; Nine Continents Medical, Inc: Consultant or Advisor; Revance: Scientific Study or Trial
Tracy M. Downs, M.D.: Nothing to disclose
Scott E. Eggener, M.D.: Janssen Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Myriad Genetics: Consultant or Advisor, Scientific Study or Trial; NxThera: Consultant or Advisor; Profound Medical: Consultant or Advisor; Genomic Health: Consultant or Advisor, Scientific Study or Trial; MDx Health: Consultant or Advisor, Meeting Participant or Lecturer
Brian Howard Eisner, MD: Ravine Group: Owner, Product Development; Gyrus/ACMI/Olympus: Consultant or Advisor; Boston Scientific: Consultant or Advisor; Bard: Consultant or Advisor; Retrophin: Consultant or Advisor
Howard B. Goldman, MD: allergan: Meeting Participant or Lecturer; astellas: Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; uroplasty: Consultant or Advisor, Meeting Participant or Lecturer; Wellspect: Consultant or Advisor; Cook: Scientific Study or Trial; american medical systems: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; axonics: Consultant or Advisor
E. Ann Gormley, MD: SUFU Foundation: Leadership Position
Wayne John G. Hellstrom MD: Endo: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Theralogix: Leadership Position; Coloplast: Consultant or Advisor, Meeting Participant or Lecturer; Lilly: Consultant or Advisor, Meeting Participant or Lecturer; American Medical Systems: Consultant or Advisor; NIH: Leadership Position; Antares: Consultant or Advisor; Auxilium: Consultant or Advisor, Scientific Study or Trial; New England Research Institutes, Inc: Other; Promescent: Consultant or Advisor; Abbvie: Consultant or Advisor; Pfizer: Consultant or Advisor; Astellas: Consultant or Advisor; Repros Therapuetics: Consultant or Advisor; Allergan: Consultant or Advisor; Menerini: Meeting Participant or Lecturer; Lipocine, Inc: Consultant or Advisor
Gerald H. Jordan, MD, FACS: Precision Medical Devices: Consultant or Advisor; Engineers and Doctors/Wallsten/PNN: Leadership Position, Consultant or Advisor; C&S Surgical: Other; American Board of Urology: Employee
Laurence H. Klotz, M.D.: Ferring: Consultant or Advisor, Scientific Study or Trial; Amgen: Consultant or Advisor, Scientific Study or Trial; Astellas: Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Meeting Participant or Lecturer, Scientific Study or Trial; Abbvie: Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Meeting Participant or Lecturer, Scientific Study or Trial
Badrinath R. Konety, MD: Axogen Inc.: Consultant or Advisor; Photocure Inc: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Takeda Inc: Consultant or Advisor
John N. Krieger, MD: Pfizer: Consultant or Advisor, Scientific Study or Trial
Jaime Landman, MD: Cook Urological: Consultant or Advisor, Owner, Product Development; Cook: Consultant or Advisor; Galil Medical: Consultant or Advisor; SurgiQuest: Leadership Position, Consultant or Advisor, Scientific Study or Trial, Investment Interest; Aesculap: Scientific Study or Trial
Gary Evan Lemack, M.D.: Astellas: Meeting Participant or Lecturer; Pfizer: Investment Interest; Allergan: Meeting Participant or Lecturer; Sophiris: Scientific Study or Trial; Medtronic: Consultant or Advisor
Yair Lotan, M.D.: abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Scientific Study or Trial
William Thomas Lowrance, M.D.: Myriad Genetics: Scientific Study or Trial; Genome Dx: Scientific Study or Trial; Argos: Scientific Study or Trial
Kevin Thomas McVary ,MD, FACS: Astellas: Scientific Study or Trial; Lilly/ICOS: Consultant or Advisor, Scientific Study or Trial; NIDDK: Scientific Study or Trial; AMS: Scientific Study or Trial; Sophris: Scientific Study or Trial
Maxwell V. Meng, M.D.: Nothing to disclose
Nicole Lara Miller, M.D.: Lumenis: Meeting Participant or Lecturer
Ajay Nehra, M.D.: International Society of Mens Health: Leadership Position; American Society of Mens Health: Leadership Position; AUA NEWS: Leadership Position; Journal of Mens Health: Leadership Position; Sexual Medicine Society of North America: Leadership Position; ICUD: Meeting Participant or Lecturer; ICUD: Meeting Participant or Lecturer; Journal of Urology: Health Publishing
Joel Byron Nelson, MD: ImaginAb: Consultant or Advisor
Mike Minh Nguyen, M.D., MPH: Nothing to disclose
Craig Stuart Niederberger, M.D.: AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE: Leadership Position, Meeting Participant or Lecturer; NexHand: Leadership Position, Investment Interest, Owner, Product Development; Ferring Pharmaceuticals: Scientific Study or Trial
John Luther Phillips, MD: Nothing to disclose
Mrs. Deborah F. Polly (STAFFLIAISON): Nothing to disclose
Arthur I. Sagalowsky, M.D.: Journal of Urology: Health Publishing; Urologic Oncology: Health Publishing; Current Urology Reports: Health Publishing; Bladder Cancer Advocacy Network: Leadership Position; American Urological Association: Meeting Participant or Lecturer; South Central Section of American Urological Association: Leadership Position
Bradley Fields Schwartz, M.D.: Cook Medical: Meeting Participant or Lecturer
Ojas Shah, M.D.: Boston Scientific: Consultant or Advisor, Meeting Participant or Lecturer; NJ Kidney Stone Center: Investment Interest; MD Agree: Consultant or Advisor, Investment Interest
Joseph A. Smith Jr., M.D. (JUEDITOR): Nothing to disclose
John Arthur Taylor III, M.D.: Nothing to disclose
Ramakrishna Venkatesh, MD: Nothing to disclose
Julian Hsin-Cheng Wan, MD: Allergan: Scientific Study or Trial
Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this enduring material for a maximum of 24.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/ or Education Content Review Committee or its subgroup
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point- counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Evidence-based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
Off label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Release Date: Issue month, 2016.
Expiration Date: Issue month, 2019.
Copyright © 2016 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
Available Credit
- 24.00 AMA PRA Category 1 Credit™
- 24.00 Non-Physician Participation